Witzel, Isabell
Loibl, Sibylle
Wirtz, Ralph
Fasching, Peter A.
Denkert, Carsten
Weber, Karsten
Lück, Hans-Joachim
Huober, Jens
Karn, Thomas
Mackelenbergh, Marion von
Marmé, Frederik
Schem, Christian
Stickeler, Elmar
Untch, Michael
Müller, Volkmar
Funding for this research was provided by:
employee of Stratifyer Molecular Oncology
Article History
Received: 6 January 2019
Revised: 23 September 2019
Accepted: 22 October 2019
First Online: 15 November 2019
Competing interests
: R.W. is employee of Stratifyer Molecular Oncology. V.M. received speaker honoraria from Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, Pfizer, Novartis, Roche, Teva, and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi-Sankyo and Eisai, Lilly, Tesaro and Nektar and research support from Novartis, Roche, Seattle Genetics, Genentech. All other authors declare that they have no conflict of interest.
: The clinical trials TECHNO and PREPARE received ethical approval (Ethics Committee, Medical Faculty of the Ludwig-Maximilians University, Munich, Germany, project no. 224/01 and 225/01, respectively) and the patient signed a consent to participate in the translational research project. The study was performed in accordance with the Declaration of Helsinki. The study was approved by each local institutional review board. A full list of the boards can be found in the supplementary material.
: The AR analysis was supported by a donation of a private person to the University Medical Center Hamburg, Department of Gynecology.
: Not applicable.
: The datasets used during the present study are available from the German Breast Group, Neu-Isenburg, Germany on reasonable request.